EP2412817A1 - Verfahren zur entfernung von viren aus einer hochkonzentrierten lösung aus monoklonalen antikörpern - Google Patents
Verfahren zur entfernung von viren aus einer hochkonzentrierten lösung aus monoklonalen antikörpern Download PDFInfo
- Publication number
- EP2412817A1 EP2412817A1 EP10755721A EP10755721A EP2412817A1 EP 2412817 A1 EP2412817 A1 EP 2412817A1 EP 10755721 A EP10755721 A EP 10755721A EP 10755721 A EP10755721 A EP 10755721A EP 2412817 A1 EP2412817 A1 EP 2412817A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- monoclonal antibody
- virus
- membrane
- solution
- antibody solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 76
- 241000700605 Viruses Species 0.000 title claims abstract description 61
- 239000012528 membrane Substances 0.000 claims abstract description 144
- 238000001914 filtration Methods 0.000 claims abstract description 63
- 150000001413 amino acids Chemical class 0.000 claims abstract description 33
- 241000125945 Protoparvovirus Species 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 239000000178 monomer Substances 0.000 claims abstract description 11
- 230000009467 reduction Effects 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 239000004475 Arginine Substances 0.000 claims description 33
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 33
- 239000000872 buffer Substances 0.000 claims description 25
- 239000002033 PVDF binder Substances 0.000 claims description 12
- 239000001913 cellulose Substances 0.000 claims description 12
- 229920002678 cellulose Polymers 0.000 claims description 12
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 12
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 11
- 238000004587 chromatography analysis Methods 0.000 claims description 10
- 229920001059 synthetic polymer Polymers 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 238000004113 cell culture Methods 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 5
- 239000004695 Polyether sulfone Substances 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- 229920002492 poly(sulfone) Polymers 0.000 claims description 5
- 229920006393 polyether sulfone Polymers 0.000 claims description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 4
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 4
- -1 polyethylene Polymers 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 abstract description 8
- 239000000243 solution Substances 0.000 description 105
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 48
- 230000000052 comparative effect Effects 0.000 description 28
- 235000001014 amino acid Nutrition 0.000 description 26
- 239000011780 sodium chloride Substances 0.000 description 24
- 239000000203 mixture Substances 0.000 description 15
- 230000003612 virological effect Effects 0.000 description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 102000008946 Fibrinogen Human genes 0.000 description 11
- 108010049003 Fibrinogen Proteins 0.000 description 11
- 229940012952 fibrinogen Drugs 0.000 description 11
- 239000012510 hollow fiber Substances 0.000 description 10
- 239000012982 microporous membrane Substances 0.000 description 9
- 241000702619 Porcine parvovirus Species 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 229940125644 antibody drug Drugs 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 230000004907 flux Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000009881 electrostatic interaction Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 4
- 229960004592 isopropanol Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000005374 membrane filtration Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 241000701931 Canine parvovirus Species 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- QZPSOSOOLFHYRR-UHFFFAOYSA-N 3-hydroxypropyl prop-2-enoate Chemical compound OCCCOC(=O)C=C QZPSOSOOLFHYRR-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VOWAEIGWURALJQ-UHFFFAOYSA-N Dicyclohexyl phthalate Chemical compound C=1C=CC=C(C(=O)OC2CCCCC2)C=1C(=O)OC1CCCCC1 VOWAEIGWURALJQ-UHFFFAOYSA-N 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000006167 equilibration buffer Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000013020 final formulation Substances 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000011045 prefiltration Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000011053 TCID50 method Methods 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000003508 chemical denaturation Methods 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000012516 mab select resin Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000011140 membrane chromatography Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000012475 sodium chloride buffer Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000011100 viral filtration Methods 0.000 description 1
- 239000013621 viresolve pro solution Substances 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
Definitions
- the present invention relates to a method for removing viruses existing in a high concentration monoclonal antibody solution and a method for producing a high concentration monoclonal antibody solution.
- Viral inactivation or removal is required for the production process of an antibody drug containing a monoclonal antibody produced by cell culture, because of concerns about contamination with viruses from raw materials or production steps.
- As a method for inactivation of viruses that may contaminate an antibody drug heat treatment, treatment using a chemical agent or the like is performed. However, viruses cannot be sufficiently inactivated by such treatment alone. Also, these methods may directly denature the antibody in the antibody drug.
- viral separation and removal using filter membranes are performed as a physical means for removing viruses without chemical denaturation.
- Non-Patent Documents 1-4 a membrane comprising natural material such as cellulose and a virus-removing membrane comprising a synthetic polymer material such as polyvinylidene fluoride (PVDF) or polyether sulfone (PES) are known (Non-Patent Documents 1-4).
- PVDF polyvinylidene fluoride
- PES polyether sulfone
- a larger amount of an antibody can be filtered within a short time and viruses can be removed with sufficiently high virus removal performance through the filtration of an antibody drug using a virus removal device that includes the above virus-removing membrane.
- a cellulose membrane is problematic in that it tends to become clogged even at an antibody concentrations of 20 mg/ml or higher, exhibits low pressure resistance, and can increase actual working pressure to only about 100 kPa, although filtration is possible, for example.
- a synthetic polymer membrane may have high pressure resistance and may function without problems even if the actual working pressure is increased to about 300 kPa.
- the synthetic polymer membrane is problematic in that it becomes clogged when the antibody concentration is increased to about 20 mg/ml, making filtration impossible to perform. Hence, filtration is generally performed at low concentrations of 10 mg/ml or lower.
- a virus-removing membrane with a small pore diameter intended for the removal of parvoviruses is required.
- Such a membrane is problematic in that it becomes easily clogged when a high concentration monoclonal antibody solution is filtered, the resulting antibody recovery rate is disadvantageously low, and a very long time is required for filtration.
- the method targeting fibrinogen comprises: adding at least one ingredient that is selected from a chaotropic substance selected from arginine, guanidine, citrulline, urea, a derivative thereof, and a salt thereof, and a compound selected from polyethoxy sorbitan ester and a derivative thereof, to a protein solution; and then filtering the protein solution using a virus-removing membrane having a pore diameter that is 15 nm or more and less than 35 nm (Patent Document 1).
- Patent document 1 discloses the assumption that the ingredient may suppress or inhibit the association of protein molecules or hydrated layer formation in the vicinity of molecules.
- intended proteins herein are blood coagulation factors such as fibrinogen and VIII factor.
- the membrane permeability of a fibrinogen solution in the presence of arginine is merely compared with the same in the absence of arginine.
- the fibrinogen concentration is less than 5 mg/ml and the subject is a low-concentration solution.
- Fibrinogen is a long, slender, thread-shaped protein having a length of nearly 60 nm, which is polymerized upon bleeding and thus is useful for hemostasis.
- a monoclonal antibody is a spherical protein having a diameter of about 15 nm and having physicochemical properties (e.g., isoelectric point and hydrophilictiy) that differ significantly from those of fibrinogen.
- Patent Document 1 is an invention relating to fibrinogen.
- the invention of Patent Document 1 is not a technology relating to monoclonal antibodies, but a technology relating to fibrinogen as a protein having properties completely differing from those of monoclonal antibodies.
- Patent Document 1 is not a good reference for the purification of monoclonal antibodies.
- Patent Document 2 describes a method for removing viruses from a fibrinogen-containing solution that may contain viruses by using a virus-removing membrane, which is characterized in that the solution containing fibrinogen contains basic amino acid or salts thereof and sodium chloride. Patent Document 2 also relates to viral removal using a membrane wherein a fibrinogen solution is used. Moreover, the protein concentration in Patent Document 2 ranges from as low as 5 mg/ml to 16.5 mg/ml, significantly differing from the high concentration monoclonal antibody solution that is an object of the present application. Furthermore, the virus-removing membrane used in Patent Document 2 is a membrane with low ability to remove small viruses such as parvoviruses, and it allows small viruses to pass through it. The sizes of viruses to be removed by the invention of Patent Document 2 are larger than those of the subject viruses of the present application. Hence, the technology of Patent Document 2 poses no problem upon filtration concerning the relationship between aggregates of monoclonal antibodies and the membrane.
- Solution conditions e.g., pH and ionic strength
- a virus-removing membrane is used in a purification process for a monoclonal antibody
- the physicochemical properties of the antibody surface and the membrane surface differ depending on solution conditions.
- the interaction between the antibody surface and the membrane surface is one reason for such a low flux, and in particular, electrostatic interaction that functions between the two affects such a low flux.
- the electric charge property of the antibody surface and the membrane surface is expressed as surface potential (zeta potential) that is changed to a positive or negative potential state depending on the relationship between the solution pH and isoelectric point (pI).
- pI of a monoclonal antibody ranges from 6 to 10.
- pH ⁇ pI a monoclonal antibody has high positive potential and acts adversely in membrane filtration. Therefore, it is thought that if the surface potential of an antibody is lowered and its electrostatic interaction with the membrane is suppressed, the flux during filtration will be improved. Meanwhile, under such solution conditions, a high concentration monoclonal antibody solution is problematic in that dispersion stability becomes poor because of the antibodies' own charges, antibodies tend to form aggregates, and thus the flux decreases over time during membrane filtration.
- an object of the present invention is to provide a method for removing even small viruses from a high concentration monoclonal antibody solution using a membrane, and thus for recovering the antibody within a short time at high yield in the form of a filtrate.
- the present inventors have discovered that viruses existing in a high concentration monoclonal antibody solution can be removed at a high removal rate through filtration with a virus-removing membrane using a monoclonal antibody solution supplemented with a basic amino acid.
- the present inventors have completed the present invention. Specifically, the following invention is provided according to the present invention.
- both suppression of the aggregate formation by antibodies and control of the relationship between the potential of the antibodies and that of the membrane become possible, a high concentration monoclonal antibody solution can be treated within a short time at high yield, and even small viruses can be removed at high removal rates.
- additional effects can be expected such that antibody drug production step can be simplified, the step can be more compact, and the cost of the step can be reduced.
- Antibodies to be used in the present invention are monoclonal antibodies. Also, monoclonal antibodies may be produced or purified by any method. Antibodies to be used in the present invention are preferably monoclonal antibodies that are prepared by culturing animal cells such as CHO. Basically, any known techniques can be used for production of monoclonal antibodies. An animal is immunized with an antigen according to a general immunization method, cells producing monoclonal antibodies are screened by a known screening method, hybridomas of these cells with tumor cells are prepared, hybridomas are cultured in large scale, so that the monoclonal antibodies can be prepared.
- monoclonal antibodies to be used herein are not limited to (mouse) monoclonal antibodies produced by hybridomas.
- monoclonal antibodies to be used herein include chimeric antibodies artificially altered for the purpose of lowering the antigenicity of heteroantibody against a human, or the like.
- a reconstructed humanized antibody can also be used for the present invention.
- Such a reconstructed humanized antibody is prepared by substituting a complementarity determining region of a human antibody with the same of an antibody of a non-human mammal such as mouse. General gene recombination techniques therefor are also known.
- a reconstructed humanized antibody can be obtained by such a known method.
- the concentration of an antibody in a monoclonal antibody solution ranges from 20 mg/ml to 100 mg/ml, preferably ranges from 20 mg/ml to 80 mg/ml, more preferably ranges from 20 mg/ml to 70 mg/ml, and further more preferably ranges from 20 mg/ml to 50 mg/ml.
- concentration of an antibody increases, the filtration rate by a virus-removing membrane tends to decrease.
- Antibody purity in a monoclonal antibody solution is 90% or more (monomer) and is more preferably 95% or more. Impurities other than monomers contained in an antibody solution are associates and aggregates that are dimers, trimers, tetramers, or multimers greater than tetramers of antibodies. When the amounts of associates or aggregates are high, a virus-removing membrane becomes clogged upon filtration, and thus high throughput cannot be obtained.
- a monoclonal antibody solution contains at least a basic amino acid.
- a basic amino acid arginine, histidine, guanidine, lysine or a derivative thereof, or a salt thereof can be used.
- a basic amino acid is preferably arginine, histidine, lysine, or a derivative thereof, or a salt thereof.
- a basic amino acid is more preferably arginine or a derivative thereof, or a salt thereof.
- the concentration of a basic amino acid in a monoclonal antibody solution preferably ranges from 10 mM to 300 mM in view of the effect of improving filterability.
- the content of a basic amino acid (with respect to antibodies) in a monoclonal antibody solution preferably ranges from 0.1 mmol/g to 20 mmol/g, more preferably ranges from 0.3 mmol/g to 10 mmol/g, and further more preferably ranges from 0.6 mmol/g to 7 mmol/g, in view of the effect of improving filterability.
- a basic amino acid in the present invention is thought to have the effect of decreasing the potential of the antibody surface and thus suppressing electrostatic interaction (electrostatic attraction) with the (-) charge of the virus-removing membrane.
- antibodies tend to associate with each other through hydrophobic interaction since electrostatic repulsion between antibodies decreases; or filterability tends to decrease because of hydrophobic interaction between antibodies and the membrane.
- a basic amino acid also has an effect of suppressing antibody-antibody hydrophobic interaction and antibody-membrane hydrophobic interaction.
- the surface potential of antibodies or a membrane is expressed as zeta potential.
- the surface zeta potential can be measured by an electrophoresis light scattering method using an ELS-Z zeta potential analyzer (Otsuka Electronics Co., Ltd.), for example, but the measurement method is not limited thereto.
- ELS-Z zeta potential analyzer Otsuka Electronics Co., Ltd.
- the zeta potential of monoclonal antibodies under given solution conditions is designated as Ei1 (mV)
- the zeta potential of a virus-removing membrane under given solution conditions is designated as Em (mV)
- the two desirably have the following relationship.
- the term "the zeta potential of a virus-removing membrane under given solution conditions” refers to "the zeta potential of the relevant virus-removing membrane under conditions in which the virus-removing membrane is filled with a solution having the same composition as that of a monoclonal antibody solution but containing no monoclonal antibodies”.
- the relationship between the zeta potential Ei1 of antibodies and the zeta potential Em of a membrane is desirably represented by 0 mV ⁇ Eil - Em ⁇ 20 mV .
- Ei1 - Em When the result of Ei1 - Em is within the range that allows interaction between the antibodies and the membrane to decrease, it is thought to have an effect of improving the filtration rate of the membrane.
- a value for Ei1 - Em of more than 20 mV causes electrostatic interaction between antibodies and the membrane to increase, having an adverse effect on filtration.
- the virus-removing membrane of the present invention is negatively charged within the pH range of the present application. Furthermore, antibodies are positively charged.
- the relationship between the zeta potential Ei1 of antibodies and the zeta potential Em of a membrane is desirably represented by - 4 % ⁇ Em ⁇ Eil ⁇ - 550 % ⁇ Em .
- the zeta potential is preferably +27 mV or higher and is more preferably +29 mV or higher.
- the surface potential (zeta potential) Ei1 of the antibodies is desirably decreased to +20 mV or lower.
- the relationship between the zeta potential of antibodies Ei0 and Ei1 is desirably represented by 10 mV ⁇ Ei0 - Ei1 ⁇ 40 mV.
- the result of Ei0 - Ei1 is lower than 10 mV, the effect of decreasing the basic potential of the antibodies is weak, and thus the expected effect of improving the filtration rate cannot be obtained.
- the pH of a monoclonal antibody solution preferably ranges from 4.0 to 7.0.
- the pH is less than 4.0 or more than 7.0, antibodies themselves can be denatured or degraded.
- a basic amino acid exhibits an effect of improving filterability within the pH range between 4.0 and 7.0 upon filtration of antibodies (contained in a solution at a high concentration) using a virus-removing membrane.
- a monoclonal antibody solution may further contain one or more types of member selected from inorganic salts, buffer ingredients, surfactants, and saccharides.
- the monoclonal antibody solution can contain NaCl, a buffer salt, or the like as an inorganic salt.
- a buffer an acetate buffer, a citrate buffer, a phosphate buffer, a Tris-HCl buffer, or the like can be used.
- concentration of an inorganic salt or the concentration of a buffer ingredient preferably ranges from 10 mM to 500 mM in terms of ionic strength.
- a nonionic surfactant such as Tween20 or Tween80 can be used.
- concentration of such a surfactant that can be contained ranges from 0.01 w% to 0.05 w%.
- saccharide e.g., a monosaccharide, a disaccharide, a trisaccharide, an oligosaccharide, or sugar alcohol
- glucose, mannose, galactose, fructose, sorbose, maltose, sucrose (saccharose), sorbitol, mannitol, dextran, or the like can be contained in an amount ranging from 1 w% to 10 w% and preferably ranging from 1 w% to 5 wt%.
- cellulose or a hydrophilized synthetic polymer can be used as material for a virus-removing membrane.
- cellulose regenerated cellulose, natural cellulose, acetic acid cellulose, and the like can be used.
- hydrophilized synthetic polymer hydrophilized polyvinylidene fluoride (PVDF), hydrophilized polyether sulfone (PES), hydrophilized polyethylene (PE), hydrophilized polysulfone (PS), or the like can be used.
- PVDF polyvinylidene fluoride
- PES hydrophilized polyether sulfone
- PE hydrophilized polyethylene
- PS hydrophilized polysulfone
- An example of a hydrophilization method is a method for introducing a hydrophilic functional group to or fixing a hydrophilic polymer to the surface of a membrane via coating, graft reaction, crosslinking reaction, or the like.
- a flat membrane or a hollow fiber membrane can be used.
- a small filter prepared by loading a container with the membrane
- the membrane used herein is preferably a hollow fiber membrane.
- a filter in which the space is partitioned by a membrane into a primary space on the inlet side for a solution to be filtered and a secondary space on the outlet side for the filtered solution can be prepared.
- a virus-removing membrane is used for filtration, it can be used in the form of the filter.
- a virus-removing membrane is required to have parvovirus removal performance of LRV4 or more and more desirably LRV5 or more.
- Examples of commercially available virus removal filters for removing parvoviruses include Planova TM 15N (Asahi Kasei Medical) and Planova TM 20N (Asahi Kasei Medical), wherein a virus-removing membrane comprises cellulose, and Virosart CPV (Sartorius) and Viresolve Pro (Millipore) that comprise hydrophilized PES.
- Parvoviruses have no envelope, so that they are physically and chemically stable. Hence, parvoviruses are resistant to heating, low pH, and treatment with a chemical agent, which are generally performed during an inactivation step of the production process for a biological preparation. Thus, there is a growing need for a method for removing parvoviruses using a virus-removing membrane as a method for removing viruses, having a mode of action that differs from that of an inactivation method.
- Parvoviruses belong to the family Parvoviridae , and they are currently known to be some of the smallest viruses (18-24 nm in diameter). Examples of parvoviruses include mouse parvovirus (MVM), porcine parvovirus (PPV), and canine parvovirus (CPV). For evaluation of the virus-removing membrane of the present application, PPV is used as a model virus.
- MMV mouse parvovirus
- PPV porcine parvovirus
- CPV canine parvovirus
- the virus removal performance of a virus-removing membrane is represented by LRV
- LRV log 10 C O / C F
- Viral concentration can be expressed with infectivity titer, the number of viral nucleic acid copies, and the like.
- examples of a method for measuring infectivity titer include a TCID50 method and a plaque method.
- the number of viral nucleic acid copies can be measured by a PCR method or the like.
- the concentration of monoclonal antibodies should be adjusted to range from 20 mg/ml to 100 mg/ml and the composition of the antibody solution should be adjusted to at least contain a basic amino acid.
- the pH of a monoclonal antibody solution preferably ranges from 4 to 7.
- the concentration of a basic amino acid preferably ranges from 0.1 mmol/g to 20 mmol/g per antibody.
- a basic amino acid is added to an antibody eluate to reach a given concentration after treatment with chromatography, so as to be able to adjust the pH as given.
- buffer exchange can also be performed by a known method so that the buffer composition of the eluate is exchanged with the composition of a solution adjusted to have given concentration of a basic amino acid and pH.
- antibody concentration and buffer exchange are simultaneously performed, so that the solution composition can also be adjusted as desired.
- pH adjustment can be performed using NaOH, HCl, inorganic acid, organic acid, and buffer.
- a buffer an acetate buffer, a citrate buffer, a phosphate buffer, or the like can be used.
- a filtration method for an antibody solution using a virus-removing membrane is preferably performed by dead-end filtration. Specifically, either constant pressure filtration using constant filtration pressure or constant velocity filtration using constant filtration velocity may be employed. Filtration is performed with filtration pressure that is the same as or below the level at which the membrane can withstand, depending on the material of a virus-removing membrane to be used herein. For example, in the case of a virus-removing membrane comprising cellulose, the optimum pressure ranges from 49 kPa (0.5 bar) to 98 kPa (1 bar). In the cases of hydrophilized PVDF, hydrophilized PES, and hydrophilized PS, the optimum pressure ranges from 98 kPa (1 bar) to 490 kPa(5bar).
- the temperature for filtration with a virus-removing membrane may be within any temperature range, as long as it has no effect on the state of an antibody solution (the antibody is not denatured).
- the temperature ranges from 4°C to 40°C and more preferably ranges from 4°C to 35°C.
- the temperature has an effect on the viscosity of an antibody solution and also has an effect on the flux upon filtration with a virus-removing membrane.
- the temperature further preferably ranges from 20°C to 35°C, depending on the antibody's own stability to temperature.
- prefiltration can also be performed with a filter comprising a membrane with a pore diameter larger than that of the virus-removing membrane.
- a filter with a larger pore diameter Planova TM 35N, Planova TM 75N (these are produced by Asahi Kasei Medical), a 0.1 ⁇ m filter, a 0.2 ⁇ m filter, or the like can be used.
- filtration can also be directly performed using a virus-removing membrane.
- antibody throughput (the amount of an antibody treated) of 2 kg/m 2 /3 hours/bar (or 98 kPa) is obtained per virus-removing membrane area, time, and filtration pressure within the above-mentioned antibody concentration, filtration pressure, and temperature ranges.
- a step of filtration with a virus-removing membrane is performed after chromatography, after concentration, or after concentration /buffer exchange.
- chromatography include column chromatography using a column filled with an ion exchange resin or a gel-filtration resin and membrane chromatography using a porous membrane on the surface of which an ion exchange group has been provided.
- separation modes for chromatography include gel filtration chromatography, ion exchange chromatography (cation exchange; CEX or anion exchange; AEX), hydrophobic interaction chromatography (HIC), affinity chromatography, metal chelate affinity chromatography, and hydroxy apatite chromatography
- An example of chromatography using a ligand is chromatography using ion exchange and hydrophobic interaction in combination.
- An concentration step can be performed according to a known method using an ultrafiltration (UF) membrane. Specifically, the step can be performed by centrifugal concentration.
- UF ultrafiltration
- a buffer exchange step can also be performed according to a known method. Specifically the buffer exchange step can be performed simultaneously with concentration using an ultrafilter membrane. The buffer exchange step can also be performed by a gel filtration method. The buffer exchange step can also be performed by a dialysis method using a dialysis membrane.
- purification treatment can also be performed by chromatography treatment. Also, even higher concentration can be achieved by UF treatment.
- Final formulation can also be performed using the same solution composition as that upon filtration with a virus-removing membrane. Also, a saccharide, a surfactant, or the like is added after filtration with a virus-removing membrane and then final formulation can also be performed. Buffer exchange with a solvent having another composition is also possible. Lyophilization can further be performed.
- Planova TM 20N (Asahi Kasei Medical) (hereinafter, denoted as Filter A) comprising a cellulose hollow fiber membrane as a virus-removing membrane and a filter (hereinafter, denoted as Filter B) comprising a hydrophilized polyvinylidene fluoride hollow fiber membrane as a virus-removing membrane were used.
- a monoclonal antibody solution was prepared according to the method described in International Patent Publication No. 04/087761 as described below ("Preparation of Monoclonal Antibody”) and then used.
- a composition comprising 49 wt% polyvinylidene fluoride resin (Kureha Corporation, T#1300) with a melt flow index (MFI) of 2.5 (g/10 ml) and 51 wt% dicyclohexyl phthalate (Osaka Organic Chemical Industry Ltd., industry product) was stirred and mixed at 70°C using a henschel mixer (Mitsui Mining Co., Ltd.; format: 20B), cooled, and then pulverized. The resultant was applied using a hopper to a co-rotating twin screw extruder (Technovel Corporation, KZW25TW-50MG-NH (-600)), melted and mixed at 210°C, and then homogeneously dissolved.
- MFI melt flow index
- dicyclohexyl phthalate and dibutyl phthalate were extracted and removed with a 58 wt% aqueous isopropylalcohol solution (Daihachi Chemical Industry Co., Ltd., industry product).
- a 58 wt% aqueous isopropylalcohol solution (Daihachi Chemical Industry Co., Ltd., industry product).
- the attached 58 wt% aqueous isopropylalcohol solution was substituted with water.
- the resultant was immersed in water and then heated at 125°C using an autoclave (Hirayama Manufacturing Corporation, HV-85) for 4 hours.
- the attached water was substituted with isopropylalcohol (Daihachi Chemical Industry Co., Ltd., industry product) and then the resultant was dried using a vacuum drier (Stec Co., Ltd.) at a temperature of 60°C, so that a hollow fiber microporous membrane was obtained.
- a vacuum drier Stec Co., Ltd.
- hydrophilization treatment was performed by a graft method for the above microporous membrane.
- the reaction solution used herein was prepared by dissolving hydroxypropyl acrylate (Osaka Organic Chemical Industry Ltd., industry product) in a 25 vol% aqueous solution of 3-butanol (Junsei Chemical Co., Ltd., industry product) so as to achieve 8 vol% hydroxypropyl acrylate, and then performing nitrogen bubbling for 30 minutes while keeping it at 45°C.
- the microporous membrane was irradiated with 25 kGy of y-ray using Co60 as a radiation source while cooling it with dry ice at -60°C.
- microporous membrane was left to stand for 15 minutes under reduced pressure of 13.4 Pa or less.
- the above reaction solution and the microporous membrane were brought into contact with each other at 60°C and then left to stand for 1 hour. Thereafter, the microporous membrane was washed with a 58 wt% aqueous isopropylalcohol solution and then subjected to 4 hours of vacuum drying at 60°C.
- a hydrophilic microporous membrane was obtained. It was confirmed that water spontaneously infiltrated the pores when the microporous membrane was brought into contact with water. Both ends of a bundle of 12 microporous membranes were sealed with polyurethane.
- the bundle was connected to a cartridge wherein the hollow fiber membranes made of polystyrene were partitioned into a space on the inlet side and a space on the outlet side, so that a filter (effective membrane area: 0.001 m 2 ) was prepared.
- the filter obtained by the above method comprising the hydrophilized PVDF hollow fiber membranes is hereinafter denoted as Filter B.
- the human monoclonal antibody was eluted (linear velocity: 500 cm/h) using 5 column volumes of 20 mmol/l sodium citrate buffer (pH 3.4).
- the eluate was neutralized with 10 mmol/l sodium phosphate buffer (pH 8.2), adjusted to pH 8.0 using 1.5 (mmol/l) Tris-HCl, and then added (linear velocity: 300 cm/h) to an anion exchange column (GE Healthcare Bioscience, Q Sepharose XL 10 mm ID ⁇ 15 cm) that had been equilibrated with 10 mmol/l Tris-HCl. After completion of addition, 3 column volumes of equilibration buffer were applied to a column (linear velocity: 300 cm/h).
- the fraction not adsorbed to the column was adjusted to pH 5.0 with 1.0 mol/l acetic acid and then the resultant was added (linear velocity: 300 cm/h) to a cation exchange column (GE Healthcare Bioscience, SP Sepharose FF, 26 mm ID ⁇ 15 cm) that had been equilibrated with 20 mmol/l sodium acetate buffer (pH 5.0).
- Cultured PK-13 cells obtained from ATCC; ATCC No. CRL-6489 were diluted with D-MEM (Invitrogen Corporation, high-glucose) (the mixture is hereinafter referred to as "3% FBS/D-MEM”) supplemented with 3 vol% bovine serum (Upstate, heated in water at 56°C for 30 minutes for inactivation and then used) and 1 vol% penicillin/streptomycin (+10000 Units/ml Penicillin, +10000 ⁇ g/ml Streptomycin, Invitrogen Corporation).
- D-MEM Invitrogen Corporation, high-glucose
- 3 vol% bovine serum Upstate, heated in water at 56°C for 30 minutes for inactivation and then used
- penicillin/streptomycin +10000 Units/ml Penicillin, +10000 ⁇ g/ml Streptomycin, Invitrogen Corporation
- each filtrate, 10-food, 10 2 -fold, 10 3 -fold, 10 4 -fold, and 10 5 -folk diluents prepared from the filtrate, and 10 2 -fold, 10 3 -fold, 10 4 -fold, 10 5 -fold, 10 6 -fold, and 10 7 -fold diluents prepared from the original solution were dispensed at 100 ( ⁇ l) per 8 wells, followed by 10 days of culture at 37°C under a 5% carbon dioxide atmosphere within an incubator.
- each PBS(-) diluent of the thus prepared erythrocyte precipitates was dispensed to all wells of the above cell culture plates. After the plates had been left to stand for 2 hours, the presence or the absence of erythrocytes adsorbed to the surfaces of cultured cell tissue was confirmed visually. Wells for which adsorption had been confirmed were determined to be wells in which viral infection had occurred. Wells for which no adsorption had been confirmed were determined to be wells in which no infection had occurred. The numbers of such wells were determined. Regarding the presence or the absence of viral infection in each of the thus obtained culture solutions, the proportion was confirmed for the filtrate, diluents thereof, or diluents of the original solution.
- Monoclonal antibody solutions were prepared using HPLC (Shimadzu Corporation, Prominence; column: TOSOH Corporation, GPC column, TSK gel G3000SWXL, mobile phase: phosphate buffer (pH 6.9)/0.3 (mol/l) aqueous sodium chloride solution) to satisfy the solution conditions of the following Examples and Comparative examples.
- HPLC Shiadzu Corporation, Prominence; column: TOSOH Corporation, GPC column, TSK gel G3000SWXL, mobile phase: phosphate buffer (pH 6.9)/0.3 (mol/l) aqueous sodium chloride solution
- the purities of the monoclonal antibody solutions were each measured on the basis of peak area ratio. The results are as shown in Table 3 below.
- Zeta potential was measured by an electrophoresis light scattering method using an ELS-Z zeta potential analyzer (Otsuka Electronics Co., Ltd.) according to the manufacturer's instructions (Reference: Otsuka Densi Web information, www/photal co. jp.).
- the zeta potential (Ei1) of antibodies under given solution conditions was calculated on the basis of mobility.
- the zeta potential (Ei0) of antibodies in a NaCl solution (pH 4, ionic strength: 0.1 mM) was found to be +37 mV.
- the zeta potential (Em) of membrane was measured using an ELS-Z zeta potential analyzer (Otsuka Electronics Co., Ltd.) similarly to the above according to the manufacturer's instructions. Specifically, the zeta potential (Em) of membrane was measured using cell units for flat-plate samples (Otsuka Electronics Co., Ltd.), the membrane was placed thereon, and then the membrane was filled with a solution having the same composition of the antibody solution but containing no antibody Under such conditions, zeta potential was measured using monitor particles (Otsuka Electronics Co., Ltd.) coated with hydroxypropyl cellulose and comprising polystyrene latex with almost zero potential (Reference: Otsuka Densi Web information, www/photal co.
- each monoclonal antibody solution was subjected to concentration and buffer composition exchange so as to satisfy the conditions of Table 1.
- monoclonal antibody purity was measured by the above method.
- PPV 0.5 vol% was added and then the resultant was stirred well.
- the solutions of Examples 1 to 7 and the solutions of Comparative examples 1 to 5 were subjected to 3 hours of dead-end filtration using Filter A having a membrane area of 0.001 m 2 under the pressure of 98 kPa (1 bar).
- the amounts of monoclonal antibodies that could be filtered (kg/ m 2 /3 hr/bar) were calculated and the results are shown in Table 1.
- PPV removal performance was evaluated by the above method.
- Table 3 Additive Antibody concentration (mg/ml) Basic amino acid concentration per antibody(mmol/g) pH Throughput (kg/m 2 /3hours /bar)
- Example 1 100 mM arginine 30 3.3 4.0 2.92
- Example 2 100 mM arginine 20 5.0 4.0 2.73
- Example 3 100 mM histidine 30 3.3 4.0 2.10
- Example 4 100 mM arginine 30 3.3 5.4 2.30
- Example 5 50 mM arginine 30 1.7 5.4 2.30
- Example 6 100 mM arginine 35 2.9 5.4 2.20
- Example 7 20 mM histidine 30 0.7 6.0 2.40 100 mM sodium chloride Comparative example 1 100 mM sodium chloride 30 0 4.0 1.58 Comparative example 2 100 mM sodium chloride 20 0 4.0 1.83 Comparative example 3 None 30 0 4.0 0.75 Comparative example 4 100 mM sodium chloride 30 0 5.4 1.26 Comparative example 5 100 m
- each monoclonal antibody solution was subjected to concentration and buffer composition exchange, so as to satisfy the conditions of Table 2.
- monoclonal antibody purity was measured by the above method.
- PPV 0.5 vol% was added, the resultant was stirred well.
- the solutions of Examples 8 to 14 and the solutions of Comparative examples 6 to 9 were subjected to 3 hours of dead-end filtration using Filter B having the membrane area of 0.001 m 2 under the pressure of 294 kPa (3 bar).
- the amounts of monoclonal antibodies that could be filtered (kg/ m 2 /3 hr/bar) were calculated and the results are shown in Table 2.
- PPV removal performance was evaluated by the above method. Furthermore, the results of measuring antibody purity are shown in Table 3.
- Table 2 Additive Antibody concentration (mg/ml) Basic amino acid concentration per antibody (mmol/g) pH Throughput (kg/m 2 /3hours /bar)
- Example 8 100 mM arginine 30 3.3 4.0 2.33
- Example 9 100 mM histidine 30 3.3 4.0 2.30
- Example 10 100 mM arginine 30 3.3 5.4 2.40
- Example 11 100 mM arginine 30 3.3 7.0 2.33
- Example 12 100 mM arginine 30 3.3 7.0 2.42 100 mM sodium chloride
- Example 13 100 mM arginine 50 2 4.0 2.30
- Example 14 100 mM arginine 70 1.4 4.0 2.10
- Comparative example 6 100 mM sodium chloride 30 0 4.0 1.90
- Comparative example 7 100 mM sodium chloride 30 0 7.0 1.67
- Comparative example 8 None 30 0 4.0 1.45 Comparative example 9 None 30 0 7.0 0.43
- Table 3 Additive
- the present invention can be used effectively as a method for removing viruses during the production process for an antibody drug.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Water Supply & Treatment (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009078171 | 2009-03-27 | ||
PCT/JP2010/002219 WO2010109920A1 (ja) | 2009-03-27 | 2010-03-26 | 高濃度モノクローナル抗体溶液中のウイルス除去方法 |
Publications (4)
Publication Number | Publication Date |
---|---|
EP2412817A1 true EP2412817A1 (de) | 2012-02-01 |
EP2412817A4 EP2412817A4 (de) | 2013-01-23 |
EP2412817B1 EP2412817B1 (de) | 2016-05-04 |
EP2412817B2 EP2412817B2 (de) | 2019-06-05 |
Family
ID=42780617
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10755721.7A Active EP2412817B2 (de) | 2009-03-27 | 2010-03-26 | Verfahren zur entfernung von viren aus einer hochkonzentrierten lösung aus monoklonalen antikörpern |
Country Status (6)
Country | Link |
---|---|
US (1) | US9056896B2 (de) |
EP (1) | EP2412817B2 (de) |
JP (1) | JP5755136B2 (de) |
CN (1) | CN102365368B (de) |
ES (1) | ES2573663T5 (de) |
WO (1) | WO2010109920A1 (de) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9359397B2 (en) | 2011-06-24 | 2016-06-07 | Asahi Kasei Medical Co., Ltd. | Method for manufacturing protein drug |
WO2017076553A1 (en) * | 2015-11-05 | 2017-05-11 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for the separation of virus compositions including depletion and purification thereof |
CN110740802A (zh) * | 2017-06-12 | 2020-01-31 | 旭化成医疗株式会社 | 含有蛋白质的溶液的过滤方法 |
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US10975368B2 (en) | 2014-01-08 | 2021-04-13 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0716762A2 (pt) | 2006-09-13 | 2013-09-24 | Abbott Lab | melhorias da cultura celular |
US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
EP2921501A1 (de) * | 2008-10-20 | 2015-09-23 | Abbvie Inc. | Isolation und Aufreinigung von Antikörpern mit Protein-A-Affinitätschromatografie |
KR101722423B1 (ko) | 2008-10-20 | 2017-04-18 | 애브비 인코포레이티드 | 항체 정제 동안의 바이러스 불활성화 |
CN102712691A (zh) * | 2009-08-06 | 2012-10-03 | 弗·哈夫曼-拉罗切有限公司 | 蛋白质纯化中提高病毒去除的方法 |
TR201810703T4 (tr) * | 2011-03-25 | 2018-08-27 | Hoffmann La Roche | Yeni protein saflaştırma yöntemleri. |
DE102011105525B4 (de) * | 2011-06-24 | 2015-03-26 | Sartorius Stedim Biotech Gmbh | Verfahren zur Abtrennung von Biopolymer-Aggregaten und Viren aus einem Fluid |
EP2889623B1 (de) * | 2012-08-24 | 2017-10-04 | The University of Tokyo | Exosomeranalyseverfahren, exosomeranalysevorrichtung und verwendung eines exosomer elektrophoresechips |
JP2016533172A (ja) * | 2013-10-03 | 2016-10-27 | タケダ ワクチン,インコーポレイテッド | 細胞株からラブドウイルスを検出および除去する方法 |
WO2015195453A2 (en) | 2014-06-16 | 2015-12-23 | Emd Millipore Corporation | Methods for increasing the capacity of flow-through processes |
WO2015195452A2 (en) | 2014-06-16 | 2015-12-23 | Emd Millipore Corporation | Single-pass filtration systems and processes |
JP6339674B2 (ja) | 2014-06-25 | 2018-06-06 | イー・エム・デイー・ミリポア・コーポレイシヨン | 小型スパイラル型フィルターエレメント、モジュール、およびシステム |
SG11201508665QA (en) | 2014-08-29 | 2016-03-30 | Emd Millipore Corp | Processes For Filtering Liquids Using Single Pass Tangential Flow Filtration Systems AndTangential Flow Filtration Systems With Recirculation of Retentate |
WO2016033546A1 (en) | 2014-08-29 | 2016-03-03 | Emd Millipore Corporation | Single pass tangential flow filtration systems and tangential flow filtration systems with recirculation of retentate |
JP7133925B2 (ja) * | 2015-03-23 | 2022-09-09 | アレクシオン ファーマシューティカルズ インコーポレイテッド | ウイルス濾過 |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001335509A (ja) * | 2000-05-31 | 2001-12-04 | Nihon Pharmaceutical Co Ltd | フィブリノーゲンを含有する溶液のウイルス除去法 |
US20030232969A1 (en) * | 2002-03-15 | 2003-12-18 | Thomas Lengsfeld | Method for separating off viruses from a protein solution by means of nanofiltration |
EP1457497A1 (de) * | 2003-03-06 | 2004-09-15 | Probitas Pharma, S.A. | Verfahren zum Entfernen von Viren in Fibrinogenlösungen und Fibrinogen erhalten durch dieses Verfahren |
WO2008008872A2 (en) * | 2006-07-14 | 2008-01-17 | Wisconsin Alumni Research Foundation | Adsorptive membranes for trapping viruses |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5945333A (ja) | 1982-09-08 | 1984-03-14 | Asahi Chem Ind Co Ltd | 再生セルロ−ス多孔膜の製造方法 |
WO1998030230A1 (fr) | 1997-01-09 | 1998-07-16 | Yoshitomi Pharmaceutical Industries, Ltd. | Compositions proteinees et procede de production |
AU2001277781A1 (en) | 2000-08-11 | 2002-02-25 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing preparations |
EP1551875A4 (de) * | 2002-06-21 | 2006-06-28 | Biogen Idec Inc | Gepufferte formulierungen zur konzentrierung von antikörpern und verfahren zu deren anwendung |
HUE027134T2 (en) * | 2002-09-11 | 2016-10-28 | Chugai Pharmaceutical Co Ltd | Method for protein purification |
JPWO2004087761A1 (ja) | 2003-03-31 | 2006-07-27 | 麒麟麦酒株式会社 | ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製 |
CN1798575A (zh) | 2003-04-04 | 2006-07-05 | 健泰科生物技术公司 | 高浓度抗体和蛋白制剂 |
US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
US8741600B2 (en) | 2007-06-19 | 2014-06-03 | Asahi Kasei Kabushiki Kaisha | Method for separation of immunoglobulin monomers |
JP5099930B2 (ja) | 2007-06-19 | 2012-12-19 | 旭化成株式会社 | 免疫グロブリン1量体の分離方法 |
-
2010
- 2010-03-26 EP EP10755721.7A patent/EP2412817B2/de active Active
- 2010-03-26 WO PCT/JP2010/002219 patent/WO2010109920A1/ja active Application Filing
- 2010-03-26 CN CN201080013920.7A patent/CN102365368B/zh active Active
- 2010-03-26 JP JP2011505900A patent/JP5755136B2/ja active Active
- 2010-03-26 US US13/260,419 patent/US9056896B2/en active Active
- 2010-03-26 ES ES10755721T patent/ES2573663T5/es active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001335509A (ja) * | 2000-05-31 | 2001-12-04 | Nihon Pharmaceutical Co Ltd | フィブリノーゲンを含有する溶液のウイルス除去法 |
US20030232969A1 (en) * | 2002-03-15 | 2003-12-18 | Thomas Lengsfeld | Method for separating off viruses from a protein solution by means of nanofiltration |
EP1457497A1 (de) * | 2003-03-06 | 2004-09-15 | Probitas Pharma, S.A. | Verfahren zum Entfernen von Viren in Fibrinogenlösungen und Fibrinogen erhalten durch dieses Verfahren |
WO2008008872A2 (en) * | 2006-07-14 | 2008-01-17 | Wisconsin Alumni Research Foundation | Adsorptive membranes for trapping viruses |
Non-Patent Citations (3)
Title |
---|
HONGO-HIRASAKI T ET AL: "Removal of small viruses (parvovirus) from IgG solution by virus removal filter Planova<(>R)20N", JOURNAL OF MEMBRANE SCIENCE, ELSEVIER SCIENTIFIC PUBL.COMPANY. AMSTERDAM, NL, vol. 278, no. 1-2, 5 July 2006 (2006-07-05), pages 3-9, XP024931434, ISSN: 0376-7388, DOI: 10.1016/J.MEMSCI.2005.10.057 [retrieved on 2006-07-05] * |
M. YUNOKI, S. YAMAMOTO, H. TANAKA, H. NISHIGAKI, Y. TANAKA, A. NISHIDA, J. ADAN-KUBO, M. TSUJIKAWA, S. HATTORI, T. URAYAMA ET AL.: "Extent of hepatitis E virus elimination is affected by stabilizers present in plasma products and pore size of nanofilters", VOX SANGUINIS, vol. 95, 9 July 2008 (2008-07-09), pages 94-100, XP002689012, * |
See also references of WO2010109920A1 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9359397B2 (en) | 2011-06-24 | 2016-06-07 | Asahi Kasei Medical Co., Ltd. | Method for manufacturing protein drug |
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US10975368B2 (en) | 2014-01-08 | 2021-04-13 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
WO2017076553A1 (en) * | 2015-11-05 | 2017-05-11 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for the separation of virus compositions including depletion and purification thereof |
US11697800B2 (en) | 2015-11-05 | 2023-07-11 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Method for the separation of virus compositions including depletion and purification thereof |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
CN110740802A (zh) * | 2017-06-12 | 2020-01-31 | 旭化成医疗株式会社 | 含有蛋白质的溶液的过滤方法 |
EP3639911A4 (de) * | 2017-06-12 | 2020-04-22 | Asahi Kasei Medical Co., Ltd. | Filtrierverfahren für eine proteinhaltige flüssigkeit |
TWI734009B (zh) * | 2017-06-12 | 2021-07-21 | 日商旭化成醫療股份有限公司 | 含蛋白質液體之過濾方法 |
CN110740802B (zh) * | 2017-06-12 | 2022-04-15 | 旭化成医疗株式会社 | 含有蛋白质的溶液的过滤方法 |
US11590452B2 (en) | 2017-06-12 | 2023-02-28 | Asahi Kasei Medical Co., Ltd. | Method for filtering protein-containing liquid |
Also Published As
Publication number | Publication date |
---|---|
JPWO2010109920A1 (ja) | 2012-09-27 |
EP2412817B1 (de) | 2016-05-04 |
WO2010109920A1 (ja) | 2010-09-30 |
US9056896B2 (en) | 2015-06-16 |
ES2573663T5 (es) | 2019-12-12 |
JP5755136B2 (ja) | 2015-07-29 |
CN102365368A (zh) | 2012-02-29 |
EP2412817B2 (de) | 2019-06-05 |
EP2412817A4 (de) | 2013-01-23 |
ES2573663T3 (es) | 2016-06-09 |
CN102365368B (zh) | 2014-07-30 |
US20120077963A1 (en) | 2012-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2412817B1 (de) | Verfahren zur entfernung von viren aus einer hochkonzentrierten lösung aus monoklonalen antikörpern | |
AU2020204244B2 (en) | A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use | |
KR101119448B1 (ko) | 단백질 정제 방법 | |
KR100501263B1 (ko) | 정맥 주사용 면역글로불린의 제조 방법 및 그 외의 면역글로불린 제품 | |
CN109069592B (zh) | 纯化胶原7的方法 | |
JP5711369B2 (ja) | 蛋白製剤の製造方法 | |
KR20140022845A (ko) | 신규 단백질 정제 방법 | |
SK287633B6 (sk) | Spôsob výroby humánneho gamaglobulínu G a humánny gamaglobulín G s inaktivovanými vírusmi | |
EP3060578A1 (de) | Antikörperreinigung | |
CN115066266A (zh) | 用环保洗涤剂灭活病毒的方法 | |
EP3498828B1 (de) | Verfahren zur behandlung einer mit schweine-circoviren verunreinigten lösung | |
TW201731523A (zh) | 包含長效紅血球生成素之組成物 | |
US20220177518A1 (en) | Method for purifying protein | |
US20220348608A1 (en) | Purification of proteins and viral inactivation | |
JP2021011446A (ja) | タンパク質含有溶液のろ過方法 | |
JP2011184299A (ja) | モノクローナル抗体を含む製剤の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20111024 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/06 20060101ALI20121212BHEP Ipc: C07K 1/34 20060101ALI20121212BHEP Ipc: C12P 21/08 20060101AFI20121212BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20130102 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/06 20060101ALI20121217BHEP Ipc: C07K 1/34 20060101ALI20121217BHEP Ipc: C12P 21/08 20060101AFI20121217BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20151201 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 796960 Country of ref document: AT Kind code of ref document: T Effective date: 20160515 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2573663 Country of ref document: ES Kind code of ref document: T3 Effective date: 20160609 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602010033088 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: BOVARD AG, CH |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20160504 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160804 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160905 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160805 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R026 Ref document number: 602010033088 Country of ref document: DE |
|
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 |
|
PLAX | Notice of opposition and request to file observation + time limit sent |
Free format text: ORIGINAL CODE: EPIDOSNOBS2 |
|
26 | Opposition filed |
Opponent name: NEUEFEIND, REGINA Effective date: 20170203 |
|
PLAF | Information modified related to communication of a notice of opposition and request to file observations + time limit |
Free format text: ORIGINAL CODE: EPIDOSCOBS2 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 |
|
PLBB | Reply of patent proprietor to notice(s) of opposition received |
Free format text: ORIGINAL CODE: EPIDOSNOBS3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170326 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
PLAY | Examination report in opposition despatched + time limit |
Free format text: ORIGINAL CODE: EPIDOSNORE2 |
|
PLBC | Reply to examination report in opposition received |
Free format text: ORIGINAL CODE: EPIDOSNORE3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170326 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 796960 Country of ref document: AT Kind code of ref document: T Effective date: 20160504 |
|
PUAH | Patent maintained in amended form |
Free format text: ORIGINAL CODE: 0009272 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: PATENT MAINTAINED AS AMENDED |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: AELC |
|
27A | Patent maintained in amended form |
Effective date: 20190605 |
|
AK | Designated contracting states |
Kind code of ref document: B2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R102 Ref document number: 602010033088 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20100326 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: FP Effective date: 20160620 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160504 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: DC2A Ref document number: 2573663 Country of ref document: ES Kind code of ref document: T5 Effective date: 20191212 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160504 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160904 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20220215 Year of fee payment: 13 Ref country code: AT Payment date: 20220225 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20220210 Year of fee payment: 13 Ref country code: FR Payment date: 20220209 Year of fee payment: 13 Ref country code: BE Payment date: 20220221 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20220401 Year of fee payment: 13 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230515 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 796960 Country of ref document: AT Kind code of ref document: T Effective date: 20190625 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 796960 Country of ref document: AT Kind code of ref document: T Effective date: 20230326 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20230331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230331 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230331 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230331 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230326 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230331 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20240209 Year of fee payment: 15 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230326 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240130 Year of fee payment: 15 Ref country code: GB Payment date: 20240201 Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20240507 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230327 |